Innovating Works

Tumor-Treg-Targeting

Financiado
Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just afew years ago would have been considered untreatable. It thereby became apparent that one specific type of immune... Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just afew years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell,so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploitthe immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application withgreat success. The clinical application of these so called check-point inhibitors, however, is accompanied by severe sideeffects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmetneed. This proposal will employ the newest developments in antibody design to target the next generation of biologics righttowards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able tospecifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncanceroustissues unaffected, and thus diminish treatment associated side-effects.The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologistswith that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. Thisgroup will lead a training network that aims at educating a new generation of researchers, who will be able to bridge theinnovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, onthe other hand, the efficient translation and clinical validations of these findings in patients. ver más
30/11/2022
UNIVERSIDAD DE NAVARRA
1M€
Duración del proyecto: 53 meses Fecha Inicio: 2018-06-01
Fecha Fin: 2022-11-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-11-30
H2020 No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto El presupuesto total del proyecto asciende a 1M€
Líder del proyecto
UNIVERSIDAD DE NAVARRA No se ha especificado una descripción o un objeto social para esta compañía.